FY2030 EPS Estimates for Prothena Lowered by HC Wainwright

Prothena Corporation plc (NASDAQ:PRTA) – Equities research analysts at HC Wainwright dropped their FY2030 earnings per share estimates for shares of Prothena in a research note issued on Friday, May 8th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will post earnings of $2.35 per share for the year, down from their prior forecast of $2.64. The consensus estimate for Prothena’s current full-year earnings is $0.69 per share.

Several other equities research analysts also recently commented on PRTA. Citizens Jmp lifted their target price on shares of Prothena from $19.00 to $20.00 and gave the stock a “market outperform” rating in a research report on Friday. Stifel Nicolaus set a $19.00 price target on shares of Prothena in a research note on Friday, March 13th. Weiss Ratings lowered shares of Prothena from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, April 27th. Citigroup reissued an “outperform” rating on shares of Prothena in a research note on Friday. Finally, Royal Bank Of Canada increased their price objective on Prothena from $11.00 to $12.00 and gave the company a “sector perform” rating in a report on Friday, February 20th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $21.78.

Prothena Trading Down 9.9%

NASDAQ:PRTA opened at $9.67 on Tuesday. The stock’s 50-day moving average is $9.98 and its 200-day moving average is $9.81. Prothena has a 1-year low of $4.32 and a 1-year high of $11.80. The stock has a market cap of $506.22 million, a P/E ratio of -3.43, a price-to-earnings-growth ratio of 0.38 and a beta of -0.23.

Prothena (NASDAQ:PRTA) last posted its earnings results on Thursday, May 7th. The biotechnology company reported $0.60 EPS for the quarter, beating the consensus estimate of ($0.31) by $0.91. Prothena had a negative return on equity of 43.44% and a negative net margin of 260.92%.The firm had revenue of $51.08 million during the quarter, compared to the consensus estimate of $0.81 million.

Institutional Investors Weigh In On Prothena

Several institutional investors and hedge funds have recently made changes to their positions in PRTA. CWM LLC grew its stake in Prothena by 650.1% during the third quarter. CWM LLC now owns 10,246 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 8,880 shares during the period. ProShare Advisors LLC acquired a new position in Prothena in the fourth quarter valued at approximately $100,000. Inscription Capital LLC bought a new position in shares of Prothena during the 3rd quarter worth approximately $102,000. PDT Partners LLC acquired a new stake in shares of Prothena during the 4th quarter worth approximately $108,000. Finally, DRW Securities LLC acquired a new stake in shares of Prothena during the 4th quarter worth approximately $114,000. Institutional investors own 97.08% of the company’s stock.

Prothena Company Profile

Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.